NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Summit Therapeutics Inc. SMMT
7 fiscal years on record · USD · FY2025 reported · SEC filings only
$-1.1B
$-323.6M
Growth
—
Revenue, FY2025 · full 7-year series below
Revenue $M
Net income $M
FY2024 · Revenue 0.0 · Net income -221.3
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2022 · Operating -10225.4% · Net -11174.8%
ROE
FY2025 · ROE -206.1%
Each USD of equity lost 206 cents this year.
The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue $B | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 |
| Operating income $B | −1.1 | −0.2 | −0.6 | −0.1 | −0.1 | −0.1 | 0.0 |
| EBITDA $B | −1.1 | −0.2 | −0.6 | −0.1 | −0.1 | −0.1 | 0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | · | 0.0 | −0.0 | −0.0 |
| Net income $B | −1.1 | −0.2 | −0.6 | −0.1 | −0.1 | −0.1 | 0.0 |
| Free cash flow $B | −0.3 | −0.1 | −0.1 | −0.0 | −0.1 | −0.0 | −0.0 |
| EPS, diluted $ | −1.44 | −0.31 | −0.99 | −0.41 | −0.67 | −0.76 | 0.63 |
| Dividend / sh $ | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | −0 | 0 |
| ROE % | −206.1 | −94.9 | −601.8 | −75.1 | −108.9 | −66.3 | 18.9 |
| Shares out B | 0.78 | 0.74 | 0.70 | 0.21 | 0.10 | 0.08 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 26 reconciliationsAUDITED
Reconciled in 7 of 19 fiscal years. 50 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
Data on record since2018